Cyclic peptides and aids vaccines

Details Cyclic peptides and aids vaccines Cyclic peptides and aids vaccines

2008-05-27

2008-05-27

Parkin, Jeffrey S. (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Cyclic peptides

C530S327000, C424S188100

Reexamination Certificate

active

07378490

ABSTRACT:
Cyclic peptides comprising, as a constituent chain or chains, one or two amino acid sequences selected from the groups consisting of the amino acid sequence Glu-Ala-Asp-Asp-Arg and the amino acid sequence Ser-Gln-Lys-Glu-Gly, and AIDS vaccines containing the cyclic peptide as an active ingredient. Preferably a cyclic dodecapeptide represented by the formula given below and an AIDS vaccine containing the cyclic dodecapeptide as an active ingredient. From the in vivo absorption and antibody formation viewpoint, active groups selected from among the carboxyl, amino and hydroxyl groups contained in the cyclic peptide is preferably bound to substituent groups. The cyclic dodecapeptide can neutralize the second receptors in the infection of human with HIV-1 virus

REFERENCES:
patent: 0 551 689 (1992-01-01), None
patent: 0 834 564 (1998-04-01), None
patent: 08-027184 (1996-01-01), None
patent: WO 97/47319 (1997-12-01), None
Feinberg, M. B., and J. P. Moore, 2002, “AIDS vaccine models: challenging challenge viruses.”, Nature Med. 8(3):207-210.
Bende, S., and M. I. Johnston, 2000, “Update: search for an AIDS vaccine.”, AIDS Reader 526-538.
Johnston, M. I., 2000, “The role of nonhuman primate models in AIDS vaccine development.”, Mol. Med. Today 6:267-270.
Moore, J. P., and D. R. Burton, 1999, “HIV-1 neutralizing antibodies: how full is the bottle?”, Nature Med. 5(2):142-144.
Burton, D. R., and J. P. Moore, 1998, “Why do we not have an HIV vaccine and how can wemake one?”, Nature Med. Vaccine Suppl. 4(5):495-498.
Letvin, N. L., 1998, “Progress in the development of an HIV-1 vaccine.”, Science 280:1875-1880.
Lee, T.-H., 1997, “Acquired immunodeficiency disease vaccines: design and development”, inAIDS: Biology, Diagnosis, Treatment and Prevention, fourth edition, DeVita, Jr., V. T., et al., eds., Lippincott-Raven Publishers, Philadelphia, PA, pp. 605-616.
Haynes, B. F., et al., 1996, “Update on the issues of HIV vaccine development.”, Annals Med. 28:39-41.
Feng, Y., Broder, C., Kennedy, P., Berger, E. Science., vol. 272. pp. 872-877. May 10, 1996.
Liu, R. et al. Cell, vol. 86. pp. 367-377. Aug. 9, 1996.
Olson, W. et al. Journal of Virology, vol. 73, No. 5. pp. 4145-4155. May 1999.
Brelot, A., Heveker, N., Pleskoff, O., Sol., N., Alizon, M. Journal of Virology, vol. 71, No. 6. pp. 4744-4751. Jun. 1997.
Biochemical and Biophysical Research Communications 285, 1309-1316 (2001).
The Journal of Biological Chemistry, vol. 278, No. 34, Issue of Aug. 22, pp. 32335-32343, 2003.
Stat Med. Jul. 30, 2003; 22(14):2281-98, On the analysis of viral load endpoints in HIV vaccine trials.
Japan Pharmacology Academy Kyushu Branch Mass Meeting Lecture Summary Collection, pp. 43.

Affiliated with

Also associated with

Rating

Cyclic peptides and aids vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclic peptides and aids vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic peptides and aids vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2806345